A Multicenter, Open-Label, Randomized Controlled Trial of a Dual Early Intervention Approach Combining Standard Care and Corticosteroids for Elderly Patients with Mild to Moderate COVID-19 (BEAT-COV Study) - Scorecard - MDSpire

A Multicenter, Open-Label, Randomized Controlled Trial of a Dual Early Intervention Approach Combining Standard Care and Corticosteroids for Elderly Patients with Mild to Moderate COVID-19 (BEAT-COV Study)

  • By

  • Qiaoling Ruan

  • Yanliang Zhang

  • Tingting Zhao

  • Feng Zhu

  • Xi Liu

  • Ran Cao

  • Yongzhong Li

  • Xiaoqiang Zhang

  • Wei Song

  • Jiawei Geng

  • Deming Zou

  • Yuanyuan Li

  • Liaoyun Zhang

  • Chao Wu

  • Yuanbo Lan

  • Xiangchun Ding

  • Fuli Huang

  • Jiqin Wu

  • Feng Sun

  • Lingyun Shao

  • Wenhong Zhang

  • March 6, 2026

  • 0 min

Share

Clinical Scorecard: A Multicenter, Open-Label, Randomized Controlled Trial of a Dual Early Intervention Approach Combining Standard Care and Corticosteroids for Elderly Patients with Mild to Moderate COVID-19 (BEAT-COV Study)

At a Glance

CategoryDetail
ConditionMild to Moderate COVID-19 in Elderly Patients
Key MechanismsCorticosteroids to reduce inflammation and prevent disease progression
Target PopulationElderly patients aged 65 years and older
Care SettingMulticenter hospitals and community healthcare centers in China

Key Highlights

  • Elderly patients have the highest hospitalization rates for COVID-19.
  • Corticosteroids may alleviate systemic inflammation in COVID-19.
  • The trial aimed to evaluate corticosteroids' effectiveness in preventing disease progression.

Guideline-Based Recommendations

Diagnosis

  • Positive SARS-CoV-2 test within 7 days prior to screening.
  • Mild or moderate COVID-19 symptoms.

Management

  • Combination of standard care and corticosteroids for eligible patients.

Monitoring & Follow-up

  • Monitor for signs of severe disease progression and adverse effects of corticosteroids.

Risks

  • Potential for severe outcomes in elderly patients with COVID-19.

Patient & Prescribing Data

Elderly patients aged 65 years and older with mild to moderate COVID-19.

Corticosteroids may be beneficial in reducing disease progression risk.

Clinical Best Practices

  • Ensure informed consent is obtained from participants or their legal representatives.
  • Stratify randomization to balance treatment groups effectively.

References

Original Source(s)

A Multicenter, Open-Label, Randomized Controlled Trial of a Dual Early Intervention Approach Combining Standard Care and Corticosteroids for Elderly Patients with Mild to Moderate COVID-19 (BEAT-COV Study)

  • by Qiaoling Ruan, Yanliang Zhang, Tingting Zhao, Feng Zhu, Xi Liu, Ran Cao, Yongzhong Li, Xiaoqiang Zhang, Wei Song, Jiawei Geng, Deming Zou, Yuanyuan Li, Liaoyun Zhang, Chao Wu, Yuanbo Lan, Xiangchun Ding, Fuli Huang, Jiqin Wu, Feng Sun, Lingyun Shao, Wenhong Zhang

  • March 6, 2026

Related Content

Impact of COVID-19 pandemic on autism spectrum disorder service providers in Qatar: challenges, insights, and lessons learned

Preclinical evaluation of a multi-epitope mRNA vaccine platform for broad and durable SARS-CoV-2 protection

Clinical Characteristics and Outcomes of Invasive Pulmonary Aspergillosis in Patients with Influenza Compared to COVID-19: A Retrospective Cohort Analysis